Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM15421/GC1134A in Fabry Disease
NCT06858397Phase 2Recruiting
- Sponsor
- GC Biopharma Corp
- Start
- May 2025
- Primary completion
- Aug 2028
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
Phase 2, open-label trial of HM15421 in Fabry disease (FD) (3 cohorts), sponsored by GC Biopharma Corp. Primary endpoint: Adverse Events at 48 weeks. Started May 2025; status: recruiting.
02
Drugs
HM15421
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT06858397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858397.